COMMUNIQUÉS West-GlobeNewswire

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
21/07/2026
Transaction expands Jupiter into a dual clinical-stage CNS company by adding a differentiated FDA-designated Novel Chemical Entity alongside its Phase II Parkinson’s disease program JUPITER, FL, July 21, 2026 (GLOBE [...]
OKYO Pharma Announces Purchase of Shares by Chairman
21/07/2026
LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002
21/07/2026
TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study
21/07/2026
750 Patients Enrolled Ahead of Plan in Pivotal Study Evaluating Symphony™ IL-6 for Early Assessment of 28-Day Sepsis Mortality Risk ACTON, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX [...]
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
21/07/2026
Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in sickle cell disease [...]
Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice
21/07/2026
Abstracts presented at American Society of Pain & Neuroscience (ASPN) annual meeting across surgical decision support and basivertebral nerve ablation Early findings from real-world evidence study demonstrate [...]
R1 Therapeutics announces commencement of global Phase 2b trial of AP306 for hyperphosphatemia in patients on dialysis
21/07/2026
AP306 is a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for hyperphosphatemia, a near-universal and serious complication in chronic kidney disease patients Study underway with first [...]
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
21/07/2026
Collaboration will evaluate Akari's PH1 payload technology in combination with Whitehawk's TOP1i payload to generate potential future development opportunities TAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- [...]
Applied Biologics Initiates Multi-Center Real-World Outcomes Study of XWRAP® Across Chronic Wound Types
21/07/2026
SCOTTSDALE, Ariz., July 21, 2026 (GLOBE NEWSWIRE) -- Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for serious diseases with significant unmet medical needs, today announced the [...]
Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
21/07/2026
-- Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of PAS-004, a Macrocyclic MEK Inhibitor, for the Treatment of Patients with MAPK Pathway Driven Advanced Solid Tumors will be presented Friday, October [...]
Kraig Biocraft Laboratories CEO Kim Thompson Featured in Just Style, a Leading Global Apparel Industry Trade Publication
21/07/2026
Interview Spotlights Company's Commercial-Scale Production Progress and Path to Transforming the Global Textile Industry ANN ARBOR, Mich., July 21, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB [...]
BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
21/07/2026
MAINZ, Germany, July 21 , 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026. Additionally, the [...]
OMEICOS’ OMT-28 Headed for Phase 3 in Primary Mitochondrial Diseases (PMD) Following Positive End-of-Phase 2 Meeting with the FDA
21/07/2026
Feedback from the U.S. Food and Drug Administration (FDA) supports acceleration of OMT-28’s development path directly into a pivotal Phase 3 study With the vast majority of PMD patients having no FDA-approved [...]
Carbios reaches milestone of 100 batches at its Industrial demonstration plant and expands its licensing offering to the textile market
21/07/2026
Validation of the "Fiber-to-Fiber" biorecycling process under conditions representative of industrial operations 100 th batch 1 successfully produced at the Clermont-Ferrand demonstration plant More than 95% conversion [...]
Enterome Phase 2 data show EO2463-induced CD8 T-cell expansion correlates with progression-free survival in patients with indolent non-Hodgkin lymphoma in the watch-and-wait setting
21/07/2026
PRESS RELEASE Magnitude of EO2463-induced CD8 T-cell expansion during monotherapy statistically significantly associated with longer progression-free survival (PFS) in patients with indolent non-Hodgkin lymphoma (iNHL) [...]
Transactions in connection with share buy-back program
21/07/2026
Company announcement no. 26 - 26 21 July 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]
Carbios franchit le cap des 100 batchs produits au sein de son démonstrateur industriel et étend son offre de licences au marché textile
21/07/2026
Validation du procédé de biorecyclage « fibre-à-fibre », dans des conditions représentatives d’une exploitation industrielle 100 ème batch 1 produit avec succès au sein du démonstrateur de Clermont-Ferrand Plus de 95 % [...]
Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed
21/07/2026
Ad hoc announcement pursuant to Art. 53 LR Second quarter Net sales grew +1% (cc 1 , +3% USD), with core operating income 1 flat (cc and USD) Sales growth driven by priority brands including Kisqali (+43% cc), Kesimpta [...]
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
21/07/2026
MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational performance for the [...]

Pages